Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2002The Neurologist

The authors formulated an assessment and intervention instrument for clinic and telephone use to enhance compliance and minimize adverse events in MS patients receiving disease-modifying therapies.

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with relapsing forms of multiple sclerosis, based on clinical experience with approximately 5000 MS…

Design

Review

Authors

EFElliot M. FrohmanTPTed PhillipsKKKristen Kokel

Discussion

Loading...

Member takes

Overview

May support structured monitoring for MS DMT adherence and safety; leaves open prospective validation before adoption.

Structured PICO

P
Population
Patients with relapsing forms of multiple sclerosis (relapsing-remitting MS or secondary progressive MS), based on clinical experience with approximately 5000 MS patients.
I
Intervention
Disease-modifying agents (interferon beta1a, interferon beta1b, and glatiramer acetate)
O
Outcome
Management strategies to mitigate adverse reactions and enhance treatment compliance

A comprehensive treatment approach and assessment instrument can help optimize the management of MS patients on disease-modifying therapies by mitigating adverse events and enhancing compliance.

Cite This Study

Frohman et al. (2002) studied this question.

synapsesocial.com/papers/6a84a48b0cb2ba000a388003https://doi.org/10.1097/00127893-200207000-00003
View Full Paper
Ask AI
Bookmark
Share